作者
Michelle Meyer, Yuan Wang, Darin Edwards, Gregory R Smith, Aliza B Rubenstein, Palaniappan Ramanathan, Chad E Mire, Colette Pietzsch, Xi Chen, Yongchao Ge, Wan Sze Cheng, Carole Henry, Angela Woods, LingZhi Ma, Guillaume BE Stewart-Jones, Kevin W Bock, Mahnaz Minai, Bianca M Nagata, Sivakumar Periasamy, Pei-Yong Shi, Barney S Graham, Ian N Moore, Irene Ramos, Olga G Troyanskaya, Elena Zaslavsky, Andrea Carfi, Stuart C Sealfon, Alexander Bukreyev
发表日期
2021/10/15
期刊
The Journal of clinical investigation
卷号
131
期号
20
出版商
American Society for Clinical Investigation
简介
The mRNA-1273 vaccine is effective against SARS-CoV-2 and was granted emergency use authorization by the FDA. Clinical studies, however, cannot provide the controlled response to infection and complex immunological insight that are only possible with preclinical studies. Hamsters are the only model that reliably exhibits severe SARS-CoV-2 disease similar to that in hospitalized patients, making them pertinent for vaccine evaluation. We demonstrate that prime or prime-boost administration of mRNA-1273 in hamsters elicited robust neutralizing antibodies, ameliorated weight loss, suppressed SARS-CoV-2 replication in the airways, and better protected against disease at the highest prime-boost dose. Unlike in mice and nonhuman primates, low-level virus replication in mRNA-1273–vaccinated hamsters coincided with an anamnestic response. Single-cell RNA sequencing of lung tissue permitted high …
引用总数
20212022202320241963
学术搜索中的文章